Phase II
“This dosing is a truly historic event—for science, for medicine, and most importantly for people living with this eye disease,” said Cynthia Collins, president and chief executive officer of Editas.
Life sciences companies from across the globe provide updates on their businesses and pipelines.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Abivax SA announced dosing of the first patient in a U.S. Phase 1/2 clinical trial of ABX196 to treat patients with hepatocellular carcinoma, the most common form of liver cancer..
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
Data position the company to start potential registrational trials with two drugs in two tumor types
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
Mid-February had a solid number of clinical trial announcements. Here’s a look.
Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
PRESS RELEASES